Study Indication: Healthy Participants

A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)

Study to compare the levels of IPN60170 (mesdopetam) in blood in healthy Japanese, Chinese and Non-Asian participants after administration of two different doses of IPN60170

This Phase 1 study is part of the global development plan, which includes plans to seek marketing approval of IPN60170 in Japan and China. The Japan Pharmaceuticals and Medical Devices Agency (PMDA) and the National Medical Products Administration (NMPA) in China request that the full pharmacokinetic (PK) profile of a new drug entity be assessed

Study to Compare the Level of Elafibranor in Blood after Repeat Administration in Japanese and non-Asian Healthy Participants

This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants after Intake of a Single Tablet

This study will evaluate the effects of food on how much test drug is able to access the circulation and reach the target area (known as bioavailability). The test drug, elafibranor (IPN60190), is in development for the treatment of primary biliary cholangitis (PBC). PBC is a rare, long-term autoimmune disease of the liver. An autoimmune

A study of radiolabelled IPN60170 (Mesdopetam) elimination pathways in healthy adult male participants

The test treatment, IPN60170 (Mesdopetam), is in development for the treatment of levodopa -induced dyskinesia in Parkinson’s Disease. Parkinson’s Disease is a progressive nervous system condition that affects movement, caused by nerve cells in a specific area of the brain called the substantia nigra deteriorating or dying. Dyskinesia is uncontrolled or involuntary muscle movements that

A study to evaluate the effect of fluvoxamine, paroxetine, and smoking on a single IPN60170 (mesdopetam) dose in healthy male participants

This study will investigate the pharmacokinetics (PK), safety, and tolerability of IPN60170 and its metabolites in smokers and nonsmokers healthy male participants. IPN60170 is being developed as a potential treatment to reduce levodopa-induced dyskinesia (LID) and psychosis in patients with Parkinson’s Disease (PD).